Abstract
Despite advances in personalized medicine and targeted therapies, therapeutic resistance remains a persistent dilemma encountered by clinicians, scientists and patients. In this article we summarize the highlights of the third Quebec Conference on Therapeutic Resistance in Cancer. This unique meeting provided researchers and clinicians with insights into: intrinsic and acquired resistance; tumor heterogeneity; complexities of biomarker-driven trials; challenges of ‘omics data analysis; and models of clinical applications of personalized medicine. Emphasized throughout the conference was the importance of collaborations – between industry and academia, and between basic researchers and clinicians – so that therapeutic resistance can be studied where it matters most, in patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call